|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.08 0.00 (0.00%) as of 4:30 Fri 1/20
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
46,090,000 |
| Market
Cap: |
3.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0847 - $0.0847 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jaguar Health is a commercial stage pharmaceuticals company focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal distress, including chronic, debilitating diarrhea. Co.'s wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals for the global marketplace from plants or plant products used in rainforest areas. Napo's marketed drug Mytesi (crofelemer 125 mg delayed-release tablets) is an oral botanical drug product approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
317 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  King Steven R. |
See Remarks |
• – – |
2024-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
178 |
1,144 |
|
- |
|
| Wolin Jonathan S. |
Chief of Staff, CCO & GC |
• – – |
2024-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
89 |
1,141 |
|
- |
|
| Chaturvedi Pravin R |
Chief Scientific Officer |
• – – |
2024-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
134 |
1,270 |
|
- |
|
| Conte Lisa A |
CEO and President |
• • – |
2024-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
600 |
4,600 |
|
- |
|
| Lizak Carol R. |
Chief Financial Officer |
• – – |
2024-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
60 |
611 |
|
- |
|
| Chaturvedi Pravin R |
Chief Scientific Officer |
• – – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
204,192 |
205,328 |
|
- |
|
| Conte Lisa A |
CEO and President |
• • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
383,605 |
387,605 |
|
- |
|
| Micek John |
Director |
– • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
68,568 |
80,701 |
|
- |
|
| Siegel Jonathan B. |
Director |
– • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
68,568 |
69,874 |
|
- |
|
| King Steven R. |
see remarks |
• – – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
159,168 |
160,133 |
|
- |
|
| Jayasuriya Anula |
Director |
– • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
68,568 |
70,286 |
|
- |
|
| Wolin Jonathan S. |
Chief of Staff, CCO & GC |
• – – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
196,628 |
197,680 |
|
- |
|
| Lizak Carol R. |
Chief Financial Officer |
• – – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
142,088 |
142,745 |
|
- |
|
| Bochnowski James J |
Director |
– • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
76,613 |
78,876 |
|
- |
|
| Jayasuriya Anula |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,718 |
1,718 |
|
- |
|
| Chaturvedi Pravin R |
Chief Scientific Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
870 |
1,136 |
|
- |
|
| King Steven R. |
Chief of Sustainable Supply |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
611 |
965 |
|
- |
|
| Bochnowski James J |
Director |
– • – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,280 |
2,263 |
|
- |
|
| Wolin Jonathan S. |
Chief of Staff, CCO & GC |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
871 |
1,052 |
|
- |
|
| Lizak Carol R. |
Chief Financial Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
431 |
657 |
|
- |
|
| Conte Lisa A |
CEO and President |
• • – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,694 |
4,000 |
|
- |
|
| Micek John |
Director |
– • – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,145 |
1,306 |
|
- |
|
| Siegel Jonathan B. |
Director |
– • – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,145 |
1,306 |
|
- |
|
| Chaturvedi Pravin R |
Chief Scientific Officer |
• – – |
2023-04-05 |
4/A |
OE |
$0.00 |
$0 |
D/D |
133 |
266 |
|
- |
|
| Conte Lisa A |
CEO and President |
• • – |
2023-04-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
600 |
1,306 |
|
- |
|
60 Records found
|
|
Page 1 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
